Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775094 | 0.84 | NCF1 (0.53) | HTTHIF1AEPAS1HPGDSIGMAR1 | |
| SCHEMBL13683480 | 0.77 | NPC1 (0.59) | HTTHRH3HIF1AEPAS1HPGD | |
| SCHEMBL15467001 | 0.74 | HRH3 (0.87) | HRH3HIF1AEPAS1HPGDSMN1; SMN2 | |
| SCHEMBL1177221 | 0.74 | HPGD (0.66) | HRH3HIF1AEPAS1HPGDNPC1 | |
| SCHEMBL426993 | 0.74 | HPGD (0.66) | HTTHRH3HIF1AEPAS1HPGD | |
| SCHEMBL5477508 | 0.74 | SMN1; SMN2 (0.63) | HTTHRH3HIF1AEPAS1HPGD | |
| SCHEMBL3828316 | 0.74 | KDM4E (0.47) | HTTHRH3HIF1AEPAS1HPGD | |
| SCHEMBL15096176 | 0.74 | FFAR1 (0.56) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1177256 | 0.73 | HPGD (0.64) | HTTHRH3HIF1AEPAS1HPGD | |
| Hydrochloric Acid SCHEMBL3858785 | 0.73 | HPGD (0.64) | HRH3HIF1AEPAS1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | HTT 1236/4885HRH3 129/4885HIF1A 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.